Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Prelude sells PersonalizeDx to Rosetta for $3.5mm in cash and stock

Executive Summary

Rosetta Genomics Ltd. paid $2mm in cash and $1.5mm in stock (500k shares) to acquire private diagnostics company CynoGen Inc. (also known as PersonalizeDx) from Prelude Corp. As a form of payment, Rosetta will also provide Prelude with some assets and services.

Deal Industry
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Urine-based Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register